|
|
5045 Orbitor Drive, Building 11, Suite 400
Mississauga, Ontario L4W 4Y4 Canada
phone:905.629.9761
fax:905.629.4959
|
|
| Symbol |
YM |
| Exchange |
TSX |
| Founded |
1994 |
| Employees |
|
|
|
| www.ymbiosciences.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Cancer-related products |
|
| Management |
| David G.P. Allan, Chairman and Chief Executive Officer & Director; Vera Belaoussoff, H.B.Sc., M.Sc., Director, Preclinical and Scientific Policy; Melanie DuBois, B.Sc., Director, Quality Assurance; Gary Floyd, Vice President, Operations; David A. Kennard, Ph.D., M.B.A., Director, European Operations |
| |
|
|
|
|
|
|
|
| Keywords |
| nimotuzumab, monoclonal antibody, hepatic carcinoma, esophageal, tesmilifene |
|
|
|
| Description |
|
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization. |
|
| Products / Services |
Its lead drug, tesmilifene, is a small molecule chemopotentiator (for taxanes and anthracyclines) currently undergoing a pivotal Phase III trial in metastatic breast cancer.The Company is developing an EGFr humanized monoclonal antibody that is being tested in glioma and pancreatic cancer in Phase II trials, has completed Phase II trials in head & neck cancer, and is expected to enter a Phase III trial in 2005. A GnRH anti-cancer vaccine is in earlier stage clinical trials.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
